Details

NameSymbolSector
LINCOLN PHARMACEUTICALS LIMITEDLINCOLNPharmaceuticals
Open
531
High
536
Low
531
Close
532.55
Volume
8725
Exchange
nse
Time
03-Oct-2025

Outlook

Score:

5.75

Rating:

FAIR

Candlestick Pattern

CandlepatternofLincolnPharmaceuticalsis
Short Line
EstimatedStoplossofLincolnPharmaceuticalsis
531
LincolnPharmaceuticalshasa
Bullishℹ
pattern.
Formationof
Short Line
candlepatternindicatesthetrenddirectionofLincolnPharmaceuticalsis
Unpredictableℹ
.

Trend

LincolnPharmaceuticalsisin
Sideways trendℹ
.
PriceofLincolnPharmaceuticalsis
Downℹ
by

2.78

%.
Target
Buy@

526.34

Sell@

572.06

Current@

532.55

Volume

ThetradevolumesofLincolnPharmaceuticalshavebecome
Deficientℹ
ThevolumetrendforLincolnPharmaceuticalsis
Bearishℹ
,buttheparticipantsare
Weak Sellersℹ
ThetradevolumeofLincolnPharmaceuticalsis

Down

by

92.77

%

Valuation

ThecurrentmarketpriceofLincolnPharmaceuticalsis
Undervaluedℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth797crandtotalassetsworth797cr,thebalancesheetofLincolnPharmaceuticalsis:
Balancedℹ
.
Cashflow
LincolnPharmaceuticalshas
Sufficientℹ
cashflowbecausethereis

Surplus

of

₹ 7cr

.Itis
Upℹ
by

0

%.
52.54% i.e. ₹ 93cr earned in operatingℹ
44.07% i.e. ₹ 78cr spent in investingℹ
3.39% i.e. ₹ 6cr spent in financingℹ
0% in otherℹ
LincolnPharmaceuticalshas
Insufficientℹ
cashflowbecauseitis

₹ 0cr

.Itis
Upℹ
by

100

%.
50.4% i.e. ₹ 63cr earned in operatingℹ
45.6% i.e. ₹ 57cr spent in investingℹ
4% i.e. ₹ 5cr spent in financingℹ
0% in otherℹ
Income
TheincomeofLincolnPharmaceuticalsis

₹ 169cr

and

Profit

is:

₹ 27cr

LincolnPharmaceuticalsProfitisupby:

145.45

%andIncomeisUpby:

4.97

%
TheincomeofLincolnPharmaceuticalsis

₹ 161cr

and

Profit

is:

₹ 11cr

LincolnPharmaceuticalsProfitisdownby:

45

%andIncomeisUpby:

3.87

%
TheincomeofLincolnPharmaceuticalsis

₹ 155cr

and

Profit

is:

₹ 20cr

LincolnPharmaceuticalsProfitisdownby:

23.08

%andIncomeisDownby:

9.36

%
By using this site you agree to the use of cookies to deliver a better site experience.